Bayer CEO Sees $15 Billion Market for Xarelto, New Blood Thinners

The market for new blood thinners including Johnson & Johnson and Bayer AG’s Xarelto could eventually reach $12 billion to $15 billion a year, Bayer Chief Executive Officer Werner Wenning said.
Bloomberg